英文品名Salbutamol+Ipratropium Bromide 名称来源 化学表述1,3-Benzenedimethanol, α1-[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy-, mixt. with (1R,3R,5S)-3-[(RS)-3-Hydroxy-2-phenylpropanoyloxy]-8-isopropyl-8-methyl-8-azoniabicyclo[3.2.1]octane bromide ...
Salbutamol/ipratropium bromidedoi:10.1007/BF03273960NoneReactions Weekly
例 句 Observe the effect of combined inhalation therapy of salbutamol and Ipratropium Bromide on children with acute asthma episode. 观察沙丁胺醇、溴化异丙托品联合吸入在儿童哮喘急性发作治疗中的疗效。 概述 基本信息 沙丁胺醇化学式为:1-(4-羟基-3-羟甲基苯基)-2-(叔丁氨基)乙醇。分子式为:C13H21NO3...
ipratropium bromide Salbutamol/ipratropium bromideSalbutamol/ipratropium bromidedoi:10.1007/s40278-015-4822-1NoneReactions Weekly
Ipratropium bromide nasal spray in non-al- lergic rhinitis: efficacy, nasal cytological response and patient evaluation on quality of life. Clin Exp Allergy 1994; 24: 1049–55. 2. Hayden FG, et al. Effectiveness and safety of intranasal ipratro- pium bromide in common colds: a randomized,...
aShe was managed with intravenous steroids (hydrocortisone), nebulised bronchodilators (salbutamol and ipratropium bromide), and intravenous aminophylline infursion. 她处理了与静脉内类固醇 (氢化可体松), nebulised支气管扩张剂 (salbutamol和ipratropium溴化物)和静脉内氨茶碱infursion。[translate]...
发送邮件 警告 序号:56-16 药品通用名称:异丙托溴铵沙丁胺醇吸入喷雾剂 英文名称/商品名:Ipratropium Bromide And Salbutamol Inhalation Spray 规格:20/100微克/揿 持证商:Boehringer Ingelheim Pharmaceuticals,Inc. 备注1:未进口原研药品 备注2:美国橙皮书 ...
pratropium bromide. Salbutamol/ipratropium bromide.Salbutamol/ipratropium bromide.This article describes a case study of a 20-year-old woman who developed metabolic acidosis during treatment with salbutamol/ipratropium bromide.EBSCO_AspReactions Weekly...
salbutamol sulphate, ipratropium bromide, aminophylline, magnesium sulphate,amoxicillin and clarithromycin.5个回答 硫酸沙丁胺醇,异丙托溴铵,氨茶碱,硫酸镁,阿莫西林和克拉霉素。2013-05-23 12:21:38 回答:匿名 salbutamol硫酸盐、ipratropium溴化物、氨茶碱、硫酸镁、阿摩西林和clarithromycin。
re childhood asthma Ipratropium bromide + salbutamol in severe childhood asthmaIpratropium bromide + salbutamol in severe childhood asthmaInpharma Weekly -doi:10.2165/00128413-199509900-00029NoneSpringer International PublishingInpharma Weekly